← Leaderboards
Chendi Li
Massachusetts General Hospital
$224,866
Attributed
$224,866
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $78.5K · FY2020–22$100K$75K$50K$25K$0
'20
'21
'22
Funding mix
By agency
NIH$224,866 · 1
By mechanism
F32$224,866 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Nabeel Bardeesy$18,920,034
- David E Fisher$28,420,496
- Xu Wu$5,954,319
- Ryan Bruce Corcoran$7,598,235
- Tatsuo Kawai$13,661,886
Others in their field
Other Emerging Leaders on “Family”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$49,374,001
- John Damon Chodera · Sloan-Kettering Inst Can Research$33,270,371
- Lynn Briscoe · Leidos Biomedical Research, Inc.$23,229,499
- Badri N Vardarajan · University Of Miami School Of Medicine$20,570,414
- Robyn Lorraine Woods · Hennepin Healthcare Research Institute$19,109,927
Research focus
FamilyApoptoticApoptosisAnti-Pd-1/Pd-L1Bcl2l11 GeneBcl-2 ProteinBaseCancer ModelCancer PatientBcl2 GeneChemotherapyClinicClinical DevelopmentClinical InvestigationClinically RelevantClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsCohortCombined Modality TherapyDependenceCell LineExcisionExperimental StudyFollow-Up Studies
Grant awards (3)
Targeting MCL-1 dependent apoptotic vulnerability of KRAS-LKB1 NSCLC$78,550
F32 · FY2022 · CA · contact PI
Targeting MCL-1 dependent apoptotic vulnerability of KRAS-LKB1 NSCLC$74,886
F32 · FY2021 · CA · contact PI
Targeting MCL-1 dependent apoptotic vulnerability of KRAS-LKB1 NSCLC$71,430
F32 · FY2020 · CA · contact PI